306 related articles for article (PubMed ID: 30819452)
1. Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist?
Piątek M; Kuśnierz K; Bieńkowski M; Pęksa R; Kowalczyk M; Nawrocki S
Crit Rev Oncol Hematol; 2019 Mar; 135():95-102. PubMed ID: 30819452
[TBL] [Abstract][Full Text] [Related]
2. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma.
Du L; DeFoe M; Ruzinova MB; Olsen JR; Wang-Gillam A
Hematol Oncol Clin North Am; 2015 Aug; 29(4):717-26. PubMed ID: 26226906
[TBL] [Abstract][Full Text] [Related]
3. Novel directions in neoadjuvant therapy for pancreas adenocarcinoma.
Yang A; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):585-601. PubMed ID: 25686370
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma.
Artinyan A; Anaya DA; McKenzie S; Ellenhorn JD; Kim J
Cancer; 2011 May; 117(10):2044-9. PubMed ID: 21523715
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.
D'Angelo FA; Antolino L; La Rocca M; Petrucciani N; Magistri P; Aurello P; Ramacciato G
Med Oncol; 2016 Mar; 33(3):28. PubMed ID: 26883935
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We?
Wolff RA
Surg Clin North Am; 2018 Feb; 98(1):95-111. PubMed ID: 29191281
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.
Hoffe S; Rao N; Shridhar R
Semin Radiat Oncol; 2014 Apr; 24(2):113-25. PubMed ID: 24635868
[TBL] [Abstract][Full Text] [Related]
9. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
Mavros MN; Moris D; Karanicolas PJ; Katz MHG; O'Reilly EM; Pawlik TM
JAMA Surg; 2021 Jul; 156(7):663-672. PubMed ID: 33787841
[TBL] [Abstract][Full Text] [Related]
11. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
[TBL] [Abstract][Full Text] [Related]
12. Role of radiation therapy in patients with resectable pancreatic cancer.
Palta M; Willett C; Czito B
Oncology (Williston Park); 2011 Jul; 25(8):715-21, 727. PubMed ID: 21874833
[TBL] [Abstract][Full Text] [Related]
13. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
14. Treatment of locoregional disease: adjuvant versus neoadjuvant.
Heinemann V
Ann Oncol; 2012 Sep; 23 Suppl 10():x141-7. PubMed ID: 22987951
[TBL] [Abstract][Full Text] [Related]
15. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma.
Blair AB; Sorber R; Rozich NS; Burkhart RA
Pancreas; 2019 Sep; 48(8):973-984. PubMed ID: 31425483
[TBL] [Abstract][Full Text] [Related]
16. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
18. Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist's Perspective.
de Jesus VHF; Riechelmann RP
Cancer Control; 2023; 30():10732748231173212. PubMed ID: 37115533
[TBL] [Abstract][Full Text] [Related]
19. Combined-modality treatment for operable pancreatic adenocarcinoma.
Pisters PW; Wolff RA; Crane CH; Evans DB
Oncology (Williston Park); 2005 Mar; 19(3):393-404, 409; discussion 409-10, 412-6. PubMed ID: 15828554
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis.
Yang SQ; Zou RQ; Dai YS; Li FY; Hu HJ
Updates Surg; 2024 Jan; 76(1):1-15. PubMed ID: 37639177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
